Company news
Erasca, Inc. news in 2023
Erasca, Inc.'s news releases, calls and decks from 2023, newest first.
Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma
December 10, 2023
Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway
November 27, 2023
Erasca Reports Third Quarter 2023 Financial Results and Business Updates
November 8, 2023
Erasca to Present at Upcoming Investor Conferences in November
November 7, 2023
Erasca to Present at the Cantor Global Healthcare Conference
September 18, 2023
Erasca to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
September 4, 2023
Erasca Doses First Patient in SEACRAFT-1 Phase 1b Trial Evaluating Naporafenib Plus Trametinib in Patients with RAS Q61X Solid Tumors
August 28, 2023
Erasca Reports Second Quarter 2023 Financial Results and Business Updates
August 9, 2023
Erasca Granted FDA Orphan Drug Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 for the Treatment of Malignant Glioma
June 21, 2023
Erasca Provides Update on Clinical Program for ERK Inhibitor ERAS-007 and Refines Pipeline
June 4, 2023
Erasca to Host Virtual Investor Event on Pipeline Updates with a Focus on ERAS-007 ERK Inhibitor
May 30, 2023
Erasca to Present Promising Preliminary HERKULES-3 Phase 1b Data at the 2023 ASCO Annual Meeting
May 24, 2023
Erasca Further Strengthens Business Leadership with Two Key Promotions
May 15, 2023
Erasca Reports First Quarter 2023 Financial Results and Business Updates
May 14, 2023
Erasca to Present at the Bank of America Securities 2023 Health Care Conference
May 1, 2023
Erasca Granted FDA Fast Track Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 in Patients with Glioblastoma
April 30, 2023
Erasca Announces Two Poster Presentations at the 2023 ASCO Annual Meeting
April 25, 2023
Erasca Announces Publication of Promising Clinical Data Supporting the Therapeutic Potential of Naporafenib in Combination with Trametinib in NRAS-Mutant Melanoma
April 24, 2023
Erasca Presents Promising Initial Phase 1b Dose Escalation Data from FLAGSHP-1 for ERAS-601 Plus Cetuximab in Patients with Advanced Solid Tumors at the 2023 AACR Annual Meeting
April 17, 2023
Erasca Strengthens Clinical and Regulatory Leadership with Two Key Appointments as Company Transitions to Late-Stage Development
April 9, 2023
Erasca Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Business Updates
March 22, 2023
Erasca Announces Poster Presentation at the 2023 AACR Annual Meeting
March 13, 2023
Erasca to Present at the Guggenheim Oncology Conference 2023
January 31, 2023
Erasca to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 3, 2023
Decks in 2023
- Investor Presentation (June 2023)
Investor deck · 35 slides · Jun 5, 2023
- Investor Presentation (January 2023)
Investor deck · 63 slides · Jan 9, 2023